Table 4.
Compd | Position | R | PARP-1 IC50 (nM)a | pIC50 ± S.D (nM) | PARP-2 IC50 (nM)a | pIC50 ± S.D (nM) |
---|---|---|---|---|---|---|
51 | - | - | 35 | 7.50 ± 0.20 | 2.1 | 8.69 ± 0.01 |
60 | - | - | 68 | 7.17 ± 0.08 | NT | - |
93 | 4- | 36 | 7.45 ± 0.10 | ~10 (50%c) | - | |
94 | 4- | 22 | 7.66 ± 0.02 | 5 | 8.32 ± 0.12 | |
95 | 4- | 51 | 7.31 ± 0.14 | >10 (33%) | - | |
96 | 3- | 88 | 7.07 ± 0.10 | >10 (18%) | - | |
97 | 3- | 97 | 7.02 ± 0.07 | >10 (24%) | - | |
98 | 4- | 28 | 7.55 ± 0.02 | >10 (44%) | - | |
99 | 4- | 4 | 8.41 ± 0.11 | 0.7 | 9.19 ± 0.03 | |
100 | 4- | >50 (33%b) | - | >10 (22%) | - | |
101 | 4- | >50 (49%) | - | >10 (48%) | - | |
102 | 4- | 30 | 7.54 ± 0.10 | >10 (44%) | - | |
103 | 4- | 18 | 7.77 ± 0.15 | 4 | 8.40 ± 0.08 | |
104 | 4- | 58 | 7.24 ± 0.05 | >10 (28%) | - | |
105 | 4- | 98 | 7.01 ± 0.02 | NT | - | |
Olad | - | - | 1.2 | 8.93 ± 0.07 | 0.5 | 9.40 ± 0.30 |
Vele | - | - | 1.5 | 8.83 ± 0.06 | <10 nM | - |
Data shown are mean values obtained from two independent experiments performed in duplicates.
% inhibition screening at a single concentration (50 nM unless otherwise specified) was performed in duplicates and data shown is an average of two independent experiments;
% inhibition screening of PARP-2, was performed at 10 nM concentration, in duplicates by one experiment.
Olaparib;
Veliparib.
Not tested (NT).